Trump tariffs: India can afford to offer its exporters a relief package
While there appears to be room for discussion on a trade deal, India should be prepared for the worst: A scenario in which the US threat of a 25%-plus tariff comes to bear. Is there anything the Indian government can do to protect exporters?
Also read: The week in charts: Trump's 25% India tariff, TCS's mass layoffs, oil on the boil
Yes. A kind of public-private arrangement could be made—with a sunset clause—for the overall cost imposed to be shared by the government and exporters so that higher prices at the other end do not depress US demand.
A support framework should be drawn up to help exporters adjust to this new normal over a period of 1-3 years.
Policy decisions would need to be taken on two scores. First, should the package be only for impacted exports to the US or for all merchandise exports?
The former could imply discrimination, while supporting the export of goods to all destinations could be justified on the need for a fillip to this broad activity in the face of global headwinds.
Second, for how long should such support last? Specifying a time-frame will spell certainty for exporters. Both will, of course, depend on the Centre's fiscal space.
After those calls are taken, a package can be devised. A narrowly aimed one need not involve any special new scheme, as existing policy programmes can be used to help tariff-affected businesses. This way, we will need only minor budget-outlay additions.
First, support can be provided through India's production-linked incentive (PLI) scheme. The utilization of funds under it was targeted at around ₹2 trillion over five years from 2020-21, but is likely to fall short. This incentive can be extended to companies that face raised US tariffs.
The payback provided under the PLI scheme can serve as compensation for firms that maintain or increase their exports to the US. The payback rate can be based on the comparative tariff disadvantage within an industry vis-a-vis competing industries in other countries.
Thus, if Vietnam has a tariff of 20% and competes in ready-made garments, this industry can be provided a payback that takes that difference into account. Its thematic contours would be similar to the PLI scheme's.
Also read: Trump's 25% tariff threat puts $87 billion in Indian exports at risk
Second, the government could deploy an interest subvention scheme, promising a credit cost payback of 1-2 percentage points.
A call can be taken on whether this should be industry-specific or only for micro, small and medium enterprises (MSMEs), which contribute significantly to India's overall exports but probably is the most vulnerable sector.
MSMEs face borrowing challenges and hence any subvention will help. Ideally, though, such a benefit should apply to all exporters.
Third, the Reserve Bank of India's (RBI) targeted long-term repo operations (TLTRO), which were largely successful during the pandemic, can be revived. The central bank could provide funds at a sub-repo or repo rate to banks, which in turn can lend to tariff-affected exporting units or industries.
This can be another way to lower their cost of credit. The funds should be short-term in nature and only for working capital purposes. This way, exporting units can become more competitive on finance costs. RBI could announce a TLTRO programme for a period of 1-2 years.
Fourth, India's credit guarantee scheme can be extended to exporters, so that banks lend them funds without hesitation. The pandemic-time Emergency Credit Line Guarantee Scheme was very popular and it worked well for MSMEs. As similar conditions arise for enterprises in tariff-hit sectors, this form of support could be considered again.
A credit backstop would mean a contingency liability for the government and so it would be a fiscal cost only in case of substantial defaults. This will also help lower the credit costs of exporters.
Fifth, the government could consider tax concessions. This can be aimed at companies with a record of exports to the US, with tax offsets allowed for income earned from exports to the US in the past three years. It could allow losses to be carried forward.
Some of these ideas may not be in compliance with World Trade Organization rules, but could still be justified by the exceptional circumstances exporters face.
Note that the US has announced variable tariff rates for different countries, which is not just unique as an idea, but has also tilted the scales in favour of some. Countries like Vietnam, Korea, Philippines, Bangladesh and Sri Lanka face lower US tariffs than India, which amounts to a major disruption.
Policy steps could offer exporters a cushion, while sunset clauses would give them time to scout for new export markets and prevent government props from leading to complacency.
Also read: Services sector may catch up with merchandise exports in FY26
Also, RBI would have to watch the rupee. The US reset could cause dollar volatility. In theory, higher tariffs should drive up US inflation and bond yields. This will attract investment from overseas, which, together with reduced US imports, should strengthen the dollar against other currencies.
Central banks will have to take a call on how much currency weakening they are okay with. A lot will depend on domestic inflation and the strength of foreign exchange reserves.
The government, meanwhile, could explore policy adjustments to provide outward shipments a large-scale fillip.
These are the author's personal views.
The author is chief economist, Bank of Baroda, and author of 'Corporate Quirks: The Darker Side of the Sun'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hans India
14 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.
The Hindu
14 minutes ago
- The Hindu
SIR in Bihar an 'invasive reconstruction of electoral roll:' Dipankar Bhattacharya
Describing the Special Intensive Revision (SIR) drive under way in Bihar as 'an invasive reconstruction of the electoral roll,' Dipankar Bhattacharya, general secretary of the Communist Party of India (Marxist-Leninist) Liberation, said States including Kerala should be on guard as it could be applied in other parts of the country as well. 'If they get away with it in Bihar, they will apply it everywhere,' he said, delivering the 24th memorial lecture in memory of the journalist N. Narendran on the topic 'Bihar: Trial run for Mass Disenfranchisement.' 'In fact, some people in Kerala and Tamil Nadu may still be believing that, well, this is something only happening in north India. If it is happening in north India, it is only a matter of time it happens here. No part of India is secure. Every State, every community, every political geography, every social equation, is vulnerable,' he said. The concept of citizenship as Indians have known it no longer remains valid as people will now be forced to prove their citizenship. The migrant workers of Bihar have emerged as one of the most vulnerable sections of electors in the SIR in Bihar, given the Election Commission of India's definition of 'ordinary resident.' This could have implications for Kerala as well, which has a large migrant population, he said. The SIR in Bihar, he said, was not just about rewriting the electoral roll, but it was about rewriting the electoral rules, he said. 'By rewriting the electoral rules, you are rewriting the entire grammar of elections in India,' he said. Mr. Dipankar Bhattacharya said that the INDIA Bloc was the need of the hour, observing that the BJP has grown at the expense of all other parties. 'If we cannot identify who the common enemy is, we will be doing so at our own peril,' he said. He underscored the need for a broad-based, sustained and multi-pronged resistance against what he described as the 'fascist offensive' of the BJP-RSS in the country. On the BJP's 'One Nation, One Election' proposal, Mr. Bhattacharya said it holds grave implications for the concepts of democracy and federalism. 'Every election has its own context. A Lok Sabha election has its own context, an Assembly election has its own context, a panchayat election will have its own context. If you bulldoze, flatten everything into one single narrative, and one single context for the whole elections, there will be nothing left of India's federalism and democracy as we have known it all these years,' he said, adding that the current challenges facing the Indian people is unlike any other in the post-Independence era.
